Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ekir.2021.06.023 http://scihub22266oqcxt.onion/10.1016/j.ekir.2021.06.023 34250317!8257403!34250317     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Kidney+Int+Rep 2021 ; 6 (9): 2305-2315 Nephropedia Template TP {{tp|p=34250317|t=2021. Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19 |pdf=|usr=}}{{34250317}} gab.com Text Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19 JO: Kidney Int Rep http://www.kidney.de/pget.php?&tw=1&pmid=34250317 #FOAvip INTRODUCTION: Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients. METHODS: We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed. RESULTS: Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged >/=65 years (45% vs. 3.2% in younger patients). Acute kidney injury was present in 27.7% of patients, but was diagnosed in 50% before treatment. No patients required remdesivir discontinuation because of adverse events. We did not find significant hepatoxicity or systemic symptoms resulting from the drug. CONCLUSION: In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renal and hepatic toxicity, but randomized trials are needed to assess its efficacy. Twit Text FOAVip Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19 ????Kidney Int Rep http://www.kidney.de/pget.php?&tw=1&pmid=34250317 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34250317 #FOAvip English Wikipedia <ref>{{Cite pmid|34250317}}</ref> Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19 #MMPMID34250317 Buxeda A; Arias-Cabrales C; Perez-Saez MJ; Cacho J; Cabello Pelegrin S; Melilli E; Aladren MJ; Galeano C; Lorenzo I; Mazuecos A; Saura IM; Franco A; Ruiz-Fuentes MDC; Sanchez-Camara LA; Siverio O; Martin ML; Gonzalez-Garcia E; Lopez V; Martin-Moreno PL; Moina I; Moral Berrio E; Moreso F; Portoles JM; Santana-Estupinan R; Zarraga S; Canal C; Sanchez-Alvarez E; Pascual J; Crespo M Kidney Int Rep 2021[Sep]; 6 (9): 2305-2315 PMID34250317show ga INTRODUCTION: Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients. METHODS: We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed. RESULTS: Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged >/=65 years (45% vs. 3.2% in younger patients). Acute kidney injury was present in 27.7% of patients, but was diagnosed in 50% before treatment. No patients required remdesivir discontinuation because of adverse events. We did not find significant hepatoxicity or systemic symptoms resulting from the drug. CONCLUSION: In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renal and hepatic toxicity, but randomized trials are needed to assess its efficacy. äUse and Safety of Remdesivir in Kidney Transplant Recipients With COVI(epmc).pdf DeepDyve Pubget Overpricing